Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9BRK0
UPID:
REEP2_HUMAN
Alternative names:
-
Alternative UPACC:
Q9BRK0; Q53EM8; Q9NYF2
Background:
Receptor expression-enhancing protein 2 plays a crucial role in endoplasmic reticulum network formation, shaping, and remodeling. It is also implicated in enhancing the cell surface expression of odorant receptors. This protein's involvement in cellular structure and function underscores its importance in biological systems.
Therapeutic significance:
Given its association with Spastic paraplegia 72, a neurodegenerative disorder marked by progressive weakness and spasticity of the lower limbs, understanding the role of Receptor expression-enhancing protein 2 could open doors to potential therapeutic strategies. Its precise function in disease pathology offers a promising avenue for targeted interventions.